These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33026927)

  • 1. Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?
    Feuer Z; Meng X; Rosenkrantz AB; Kasivisvanathan V; Moore CM; Huang R; Deng FM; Lepor H; Wysock JS; Huang WC; Taneja SS
    J Urol; 2021 Mar; 205(3):740-747. PubMed ID: 33026927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative Prebiopsy Magnetic Resonance Imaging and Risk of Significant Prostate Cancer: Baseline and Long-Term Followup Results.
    Buisset J; Norris JM; Puech P; Leroy X; Ramdane N; Drumez E; Villers A; Olivier J
    J Urol; 2021 Mar; 205(3):725-731. PubMed ID: 33080153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance.
    Radtke JP; Kuru TH; Boxler S; Alt CD; Popeneciu IV; Huettenbrink C; Klein T; Steinemann S; Bergstraesser C; Roethke M; Roth W; Schlemmer HP; Hohenfellner M; Hadaschik BA
    J Urol; 2015 Jan; 193(1):87-94. PubMed ID: 25079939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer.
    Hofbauer SL; Maxeiner A; Kittner B; Heckmann R; Reimann M; Wiemer L; Asbach P; Haas M; Penzkofer T; Stephan C; Friedersdorff F; Fuller F; Miller K; Cash H
    J Urol; 2018 Oct; 200(4):767-773. PubMed ID: 29733838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
    Mertan FV; Greer MD; Shih JH; George AK; Kongnyuy M; Muthigi A; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy.
    Pepe P; Garufi A; Priolo GD; Galia A; Fraggetta F; Pennisi M
    J Urol; 2018 Oct; 200(4):774-778. PubMed ID: 29679618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Followup of Men with PI-RADS™ 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy.
    Meng X; Chao B; Chen F; Huang R; Taneja SS; Deng FM
    J Urol; 2021 Mar; 205(3):748-754. PubMed ID: 33080145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
    Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
    BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification.
    Mendhiratta N; Rosenkrantz AB; Meng X; Wysock JS; Fenstermaker M; Huang R; Deng FM; Melamed J; Zhou M; Huang WC; Lepor H; Taneja SS
    J Urol; 2015 Dec; 194(6):1601-6. PubMed ID: 26100327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the Number of Cores Targeted During Prostate Magnetic Resonance Imaging Fusion Target Biopsy.
    Kenigsberg AP; Renson A; Rosenkrantz AB; Huang R; Wysock JS; Taneja SS; Bjurlin MA
    Eur Urol Oncol; 2018 Oct; 1(5):418-425. PubMed ID: 31158081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Utility of 4Kscore
    de la Calle CM; Fasulo V; Cowan JE; Lonergan PE; Maggi M; Gadzinski AJ; Yeung RA; Saita A; Cooperberg MR; Shinohara K; Carroll PR; Nguyen HG
    J Urol; 2021 Feb; 205(2):452-460. PubMed ID: 32897802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction.
    Distler FA; Radtke JP; Bonekamp D; Kesch C; Schlemmer HP; Wieczorek K; Kirchner M; Pahernik S; Hohenfellner M; Hadaschik BA
    J Urol; 2017 Sep; 198(3):575-582. PubMed ID: 28373135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate.
    Ullrich T; Quentin M; Arsov C; Schmaltz AK; Tschischka A; Laqua N; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
    J Urol; 2018 Mar; 199(3):691-698. PubMed ID: 28941924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.
    Recabal P; Assel M; Sjoberg DD; Lee D; Laudone VP; Touijer K; Eastham JA; Vargas HA; Coleman J; Ehdaie B
    J Urol; 2016 Aug; 196(2):374-81. PubMed ID: 26920465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variation in Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Outcomes in Asian American Men: A Multicenter Study.
    Gross MD; Marks LS; Sonn GA; Green DA; Wang GJ; Shoag JE; Cabezon E; Margolis DJ; Robinson BD; Hu JC
    J Urol; 2020 Mar; 203(3):530-536. PubMed ID: 31502942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS™ 5 and Prostate Specific Antigen Density Greater than 15.
    Tafuri A; Iwata A; Shakir A; Iwata T; Gupta C; Sali A; Sugano D; Mahdi AS; Cacciamani GE; Kaneko M; Cai J; Ukimura O; Duddalwar V; Aron M; Gill IS; Palmer SL; Abreu AL
    J Urol; 2021 Aug; 206(2):289-297. PubMed ID: 33818141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.